Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: The autocrine motility factor receptor delays the pathological progression of Alzheimer’s disease via regulating the ubiquitination-mediated degradation of APP

Fig. 1

AMFR levels in APP/PS1 mice and in the serum and CSF of AD patients. A AMFR mRNA levels in the hippocampus of WT (n = 6) and APP/PS1 (n = 6) mice in different age periods. Data are shown as mean ± SEM from three independent experiments (*P < 0.05). B AMFR protein levels in the hippocampus of WT (n = 6) and APP/PS1 (n = 6) mice in different age periods. Data are shown as mean ± SEM from three independent experiments (*P < 0.05, ****P < 0.0001). C Relationship between the serum AMFR concentration (X-axis) and CSF AMFR concentration (Y-axis) of participants (n = 60). D Serum AMFR levels of patients with different stages of AD by ELISA (HC, n = 40; MCI, n = 40; AD, n = 40). Data are shown as mean ± SEM (**P < 0.01, ***P < 0.001). E CSF AMFR levels of patients with different stages of AD by ELISA (NC, n = 35; MCI, n = 30; AD, n = 35). Data are shown as mean ± SEM (*P < 0.05)

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193